Caris Life Sciences is an AI-driven precision medicine company that performs comprehensive molecular profiling for oncology through tissue-based and blood-based sequencing platforms, helping oncologists and biopharma partners identify personalized cancer treatments. The company generates revenue primarily through per-sample testing fees from clinical customers (hospitals, cancer centers, and community practices), data licensing agreements with pharmaceutical and research institutions, and strategic partnerships for drug development and companion diagnostic validation. Caris differentiates itself through its proprietary clinico-genomic dataset spanning over a million patient cases, FDA-approved diagnostic assays, proprietary AI bioinformatics tools, and dual-modality profiling capabilities that enable both therapy selection and drug discovery support across its clinical services, data licensing, and discovery partnerships.